Allergen-specific T cell response modulation (null)

Molecular Classification

Other (immunological process, not a single molecule or receptor), Cell-mediated immune modulation

Other Names

Allergen-specific T cell regulation, Modulation of allergen-reactive T cells, Antigen-specific T cell immune regulation

Disease Roles

AllergyInflammationOther (immune regulation in asthma, autoimmune diseases)

Allergen-specific T cell response modulation Overview

This entry is not a single molecular target such as a receptor or enzyme, but a biological process describing the modulation of T cell responses specific to allergens. This modulation is accomplished by several cell types and mechanisms, notably by the induction of allergen-specific regulatory T cells (Tregs) that secrete regulatory cytokines IL-10 and TGF-β, thereby suppressing pro-inflammatory T cell responses (Th2, Th1) and contributing to peripheral immune tolerance[2]. B cells also play a key role in downregulating allergen-specific CD4^+^ T cell responses, primarily through regulatory cytokines and antigen presentation[1]. Successful allergen-specific immunotherapy leverages this pathway, leading to clinical improvement by reducing allergic inflammation and symptoms. However, this is a functional immune process, not an individual molecular entity[1][2]. **Key point:** This "target" is a process involving multiple molecular actors (Tregs, B cells, cytokines) and not a canonical receptor or drug target, thus is_incorrect = true for the requested structured information format.

Mechanism of Action

Induction of allergen-specific regulatory T cells (Treg) that secrete IL-10 and TGF-β, suppressing effector T cell (Th1, Th2, Th17) activity[2] Skewing of T cells from a pro-inflammatory (Th2/Th1) phenotype to a regulatory phenotype[2] Suppression via B-cell–dependent presentation and modulation (through regulatory cytokine production)[1] Blocking IgE activation via IgG4/IgG1 induction[2]

Biological Functions

Immune response

Peripheral tolerance

Regulation of inflammation

Suppression of T helper cell activation

Cytokine secretion (e.g., IL-10, TGF-β)

Disease Associations

Allergy

Inflammation

Other (immune regulation in asthma, autoimmune diseases)

Safety Considerations

Potential risk of immunosuppression leading to infection or reduced responsiveness to pathogens[2]
Risk of anaphylaxis during allergen immunotherapy[2]
Therapeutic window and dose tailoring needed to avoid adverse immune consequences[2]

Interacting Drugs

Allergen-specific immunotherapy (AIT)[2]

Peptide immunotherapy[2]

Experimental biologics such as IL-10 or TGF-β modulators[2]

Associated Biomarkers

Biomarker
Increased levels of IL-10 and TGF-β in supernatants of allergen-stimulated PBMCs[1][2]
Expansion or function of FOXP3^+^CD4^+^CD25^+^ Treg cells[2]
Allergen-specific IgG4 (as a marker of successful immunotherapy)[2]